Furthermore, somatic mutations of Keap1, a characteristic of certain cancer phenotypes [32,33], result in constitutive Nrf2 activation, as does the silencing of Keap1 expression by miRNAs [34,35], or by epigenetic hyper-methylation of the Keap1 promoter [36]. Here, NFE2L2 is linked to cancer.